EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.
European Association for the Study of the Liver
https://pubmed.ncbi.nlm.nih.gov/29653741/Actively Recruiting
Led by Massachusetts General Hospital · Updated on 2026-03-13
50
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are evaluating two approaches for giving intravenous IV fluids to patients with acute kidney injury AKI in cirrhosis. This pilot randomized trial compares a Volume Assessment Guidance Algorithm VAGA recommendation versus standard doses of IV albumin to study safety, effectiveness, and feasibility. The study focuses on patients with AKI and decompensated cirrhosis and measures outcomes like albumin amount used, kidney injury response, survival, and use of renal replacement therapy or liver transplant. Participants will be randomly assigned to receive either a one-time VAGA-based recommendation or standard care IV albumin at 1 gram per kilogram per day for two days, up to 100 grams per day. The VAGA group may be advised to stop fluid resuscitation, use crystalloid fluids, or use colloid fluids based on clinical guidelines. Both groups will be monitored at 48 hours after randomization, at hospital discharge, and 90 days post-randomization to assess albumin usage, adherence to guidance, and clinical outcomes. Participants will be evaluated through clinical assessments and data collection during hospital stay and follow-up visits. Researchers will track the amount of IV albumin given, adherence to the assigned treatment recommendations, kidney injury response, vital status, and events like renal replacement therapy or liver transplant up to 90 days. Safety outcomes including adverse events will be reviewed up to hospital discharge and 90 days. The total study duration for each participant includes hospitalization and a 90-day follow-up period.
CONDITIONS
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Massachusetts General Hospital
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Volume Assessment Guidance Algorithm (VAGA) recommendation | Standard of care IV albumin recommendation | Crystalloid‑first resuscitation |
|---|---|---|---|
| What it is | A recommendation-driven algorithm (VAGA) to guide whether to withhold fluids or choose crystalloid or colloid resuscitation | Guidance to administer 1 g/kg/day IV albumin (max 100 g/day) for two days | Initial use of crystalloids for volume resuscitation before albumin in AKI with cirrhosis, per expert consensus |
| Role in trial | Investigational arm guiding resuscitation approach | Control arm following albumin‑based standard guidance | Not part of trial but reflects current guideline‑based standard practice |
| Primary use | To guide fluid resuscitation choice in AKI among cirrhosis patients | To provide IV albumin as a resuscitation strategy over two days | First‑line fluid choice to restore volume before albumin administration |
| How it is given or performed | One‑time recommendation to treating team to select no fluids, crystalloid, or colloid based on algorithm | IV albumin dosed at 1 g/kg/day (up to 100 g) for two consecutive days | Crystalloids administered first as fluid choice, with albumin reserved if needed |
| Evidence supporting use | Efficacy is unknown; trial is exploring feasibility, albumin use, AKI response, safety and outcomes | Efficacy remains to be evaluated in trial as comparator to VAGA approach | Guidelines support use to restore volume early but do not define superiority to albumin in AKI specific to cirrhosis |
| Important limitations | Unproven efficacy and safety; algorithm acceptance by clinicians unclear | Comparator may not reflect newer guideline shift favoring crystalloids first | Evidence specific to cirrhosis‑related AKI outcomes comparing crystalloids to albumin remains limited |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 48 hours
Participants receive initial resuscitation treatment based on a volume assessment guidance algorithm or standard of care IV albumin repletion.
1 baseline visit and 1 follow-up visit at 48 hours
Duration - Up to hospital discharge or event
Participants are assessed for treatment efficacy and safety at the time of hospital discharge or at initiation of renal replacement therapy or liver transplant.
1 visit (in-person) at hospital discharge or event
Duration - Up to 90 days after randomization
Participants are followed for clinical outcomes including survival, renal replacement therapy initiation, and liver transplant status up to 90 days after randomization.
Assessments at 90 days after randomization
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
European Association for the Study of the Liver
https://pubmed.ncbi.nlm.nih.gov/29653741/Scott W Biggins, Paulo Angeli, Guadalupe Garcia-Tsao...
https://pubmed.ncbi.nlm.nih.gov/33942342/Mitra K Nadim, John A Kellum, Lui Forni...
https://pubmed.ncbi.nlm.nih.gov/38527522/Massachusetts General Hospital
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor